DarioHealth Presents Three New Studies Demonstrating Improved Health in Users with Multiple Conditions at the American Diabetes Association's 82nd Scientific Sessions

Rhea-AI Summary

DarioHealth Corp. (Nasdaq: DRIO) highlighted breakthroughs in chronic condition management at the American Diabetes Association's 82nd Scientific Sessions on June 3-7, 2022. Three studies revealed significant enhancements in glucose control and reductions in blood pressure for users facing diabetes and hypertension. Key findings include:

• Two-thirds of users improved systolic blood pressure by 13 mmHg.
• High-risk Type 2 diabetes users reduced blood glucose by 15%.
• Average blood glucose decreased by 14%-15% across diverse ethnicities.

The integrated solutions demonstrate Dario's potential to transform chronic condition management.

Positive

• Two-thirds of users improved systolic blood pressure by 13 mmHg and diastolic by 8 mmHg.
• 38.7% lowered their hypertension by one stage.
• High-risk Type 2 diabetes users reduced average blood glucose readings by 15%.
• Average blood glucose decreased by 14% for White users and 15% for Black, Latino and Asian users.

Negative

• None.

The studies demonstrated significant improvement in glucose control and reductions in blood pressure for users managing diabetes and hypertension and improvement in clinical measures for users with diabetes, stress and depression.

The third study demonstrates that the Dario solution has similar positive impact on diabetes across ethnicities.

NEW YORK, June 3, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today three new research studies presented at the American Diabetes Association's ("ADA") 82^nd Scientific Sessions being held June 3^rd to 7^th, 2022 in New Orleans, Louisiana.

Two of the new studies add to Dario's growing body of evidence in support of an integrated approach to managing multiple chronic conditions by examining the impact of Dario's solution on users with co-occurring physical and mental conditions. The third study analyzed the impact across the ethnicities of users living with Type 2 diabetes.

"We are thrilled to present several new studies showcasing Dario's ability to positively impact health and outcomes across a wide range of factors. Our deepening knowledge about the importance of an integrated solution approach has enormous potential to change the way people manage chronic conditions, and we are proud to share further insights with the scientific community this week," said Yifat Hershcovitz, PhD., Scientific and Clinical Director at Dario and supervisor of the studies.

"Dario's solutions are continuously proven to be highly effective across an ever-expanding set of conditions and circumstances. Together, these studies offer a deeper understanding of the value Dario can provide to our users and partners through a single integrated platform," said Omar Manejwala, MD, Chief Medical Officer at Dario.

Improving Health in Users with Diabetes and Hypertension

More than two thirds of people living with Type 2 diabetes also report high blood pressure, and the bi-directional impacts are well-documented. Dario's latest research provides new data to support the co-management of these conditions in a single solution. The study examined a group of users with diabetes, and stage 1 and above hypertension, to understand the impact of using a single solution on both conditions, and results showed significant improvements for both hypertension and diabetes after six months:

• Two thirds of users improved their systolic blood pressure by 13 mmHg and diastolic by 8 mmHg
• 38.7% lowered their hypertension by one stage
• A subgroup of users with high-risk Type 2 diabetes reduced average blood glucose readings by 15%

The research demonstrates that Dario's integrated approach to managing chronic conditions in one solution offers significant benefits for users with co-occurring conditions.

Improving Health in Users with Diabetes and Depression and/or Stress  

Diabetes is closely linked with stress and symptoms of depression, and conversely, the presence of depression can lead to poor outcomes in people living with diabetes. Dario examined the outcomes of users living with high-risk diabetes and self-reported stress and/or depression and found that users reduced their average blood glucose by 13% after one year. This study indicates that Dario's holistic support focused on behavior change can positively impact outcomes for users living with diabetes and depression and/or stress.

Measuring Impact Across Ethnicities

A third study examined the impact on blood sugar readings in users with high-risk Type 2 diabetes across ethnicities as reported in Dario's app: White, Black, Latino or Asian. The research found that average blood glucose readings were significantly reduced by 14% for White users and 15% for Black, Latino and Asian users. The evidence demonstrates the ability of Dario's solution to improve self-care across diverse populations.

You can learn more about the ADA Scientific Sessions by visiting https://professional.diabetes.org/scientific-sessions.

About DarioHealth Corp.

DarioHealth Corp. (NASDAQ:DRIO) is a leading digital therapeutics (DTx) company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition platform. Our platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. 

Our user-centric platform offers people continuous and customized care for health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention, and results.  Making the right thing to do the easy thing to do.

Dario provides its highly user rated solutions globally to health plans and other payors, self-insured employers, providers of care and directly to consumers.  To learn more about DarioHealth and its digital health solutions, or for more information, visit http://dariohealth.com.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the potential benefits that may be realized by users utilizing the Dario platform. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact
Suzanne Bedell
VP Marketing
suzanne@dariohealth.com
+1-347-767-4220

Media Contact:
Scott Stachowiak
Scott.Stachowiak@russopartnersllc.com
+1-646-942-5630

View original content:https://www.prnewswire.com/news-releases/dariohealth-presents-three-new-studies-demonstrating-improved-health-in-users-with-multiple-conditions-at-the-american-diabetes-associations-82nd-scientific-sessions-301560874.html

SOURCE DarioHealth Corp.

FAQ

What studies did DarioHealth present at the ADA Scientific Sessions 2022?

DarioHealth presented three studies showcasing the positive impacts of their digital therapeutics on diabetes and hypertension management.

What were the outcomes for users managing diabetes and hypertension using Dario's solutions?

Users showed significant improvements, with two-thirds reducing systolic blood pressure and high-risk diabetes users decreasing blood glucose levels by 15%.

How did DarioHealth's solutions perform across different ethnicities?

The studies demonstrated a reduction in average blood glucose readings by 14% for White users and 15% for Black, Latino, and Asian users.

What is the significance of DarioHealth's integrated approach to chronic condition management?

The integrated approach offers a holistic solution for users managing multiple chronic conditions, improving health outcomes effectively.

When were the findings from DarioHealth's studies announced?

The findings were announced during the American Diabetes Association's 82nd Scientific Sessions held from June 3 to 7, 2022.